Drug maker AstraZeneca, seller of the Seroquel antipsychotic drug, suppressed clinical studies showing its drug significantly increased the risk of diabetes, say internal e-mails.
As Bloomberg is reporting today, employee emails that were unsealed as part of a lawsuit reveal AstraZeneca deliberately hid at least three studies that established a significant link between its Seroquel drug and the onset of diabetes in patients. This fact was blatantly admitted in a 1999 e-mail sent by an AstraZeneca official.
The Wall Street Journal is also reporting today that "AstraZeneca instructed its U.S. sales representatives to tell doctors that its powerful psychiatric drug, Seroquel, didn't cause diabetes even though a company physician had at one point stated years earlier that such a link was probable in some individuals."
